HALO
Halozyme Therapeutics Inc
Price:  
49.50 
USD
Volume:  
1,418,017.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

HALO WACC - Weighted Average Cost of Capital

The WACC of Halozyme Therapeutics Inc (HALO) is 8.8%.

The Cost of Equity of Halozyme Therapeutics Inc (HALO) is 10.00%.
The Cost of Debt of Halozyme Therapeutics Inc (HALO) is 4.30%.

Range Selected
Cost of equity 8.60% - 11.40% 10.00%
Tax rate 11.30% - 18.90% 15.10%
Cost of debt 4.00% - 4.60% 4.30%
WACC 7.7% - 9.9% 8.8%
WACC

HALO WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 1.03 1.16
Additional risk adjustments 0.0% 0.5%
Cost of equity 8.60% 11.40%
Tax rate 11.30% 18.90%
Debt/Equity ratio 0.24 0.24
Cost of debt 4.00% 4.60%
After-tax WACC 7.7% 9.9%
Selected WACC 8.8%